We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Eli Lilly’s Plaque-Buster Donanemab Shows Steady Progress
Eli Lilly’s Plaque-Buster Donanemab Shows Steady Progress
The FDA’s recent approval of Biogen’s Alzheimer’s disease treatment Aduhelm has encouraged a new roster of contenders, including Eli Lilly’s Donanemab, a relative newcomer to the antiamyloid antibody space.